Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Study Finds Lower Vaccine Uptake in States With Higher Rates of HPV-Related Cervical Cancer

      November 12, 2014
      By Christina Izzo
      Article

      New data has shown that states that have higher rates of cervical cancer incidence and mortality also have low HPV vaccination rates among young women.

      Jennifer L. Moss, MSPH

      New data has shown that states that have higher rates of cervical cancer incidence and mortality also have low HPV vaccination rates among young women.

      The data were presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved.

      “Cervical cancer incidence and mortality rates vary widely by state,” Jennifer L. Moss, MSPH, a doctoral student in the Department of Health Behavior at the University of North Carolina Gillings School of Global Public Health in Chapel Hill, said in a statement. “Our data show that adolescent girls remain vulnerable to disease in areas where women already have a higher risk of developing and dying from cervical cancer. If more adolescents, both girls and boys, in these states received an HPV vaccine, their risk of HPV-related cancers would drop dramatically.”

      Moss and colleagues collected state-based data on HPV vaccination rates from the National Immunization Survey—Teen and on cancer rates in different states from the US Cancer Statistics database.

      The research showed that as cervical cancer incidence rates increased, HPV vaccine initiation rates among girls decreased.

      “For example, in a state like Massachusetts, about 6 per 100,000 women develop cervical cancer each year and 69% of teen girls have initiated HPV vaccination,” said Moss. “However, in states with higher rates of cervical cancer incidence, such as Arkansas, where the rate is 10 per 100,000 women, vaccination is much lower—41% of teen girls.”

      The study also found that HPV vaccine initiation was lower among girls living in states with higher cervical cancer mortality rates, higher proportions of non-Hispanic black residents, and lower proportions of high-income residents.

      Completion of the three-dose course of HPV vaccine was higher in states with greater levels of adolescent contact with the healthcare system.

      “Teens don’t visit their healthcare providers as often as younger children, so increasing the frequency and efficiency of preventive visits is really important for HPV vaccination and cancer prevention,” Moss said. “We know that a healthcare provider’s recommendation is the single biggest influence on whether an adolescent receives an HPV vaccine. So, we hope that the findings of our study impress upon clinicians, especially those practicing in states with higher cancer rates, that cancer prevention means recommending HPV vaccination to adolescent patients at every visit.”

      The study also gathered data on HPV vaccine initiation coverage for boys. The results showed that HPV vaccine initiation among boys was lower in states with higher proportions of non-Hispanic white residents and lower proportions of residents of “other” race/ethnicity, but HPV vaccine initiation among boys was not associated with states’ HPV-related cancer incidence or mortality.

      However, since initiation among boys and girls was highly correlated, it is possible that the pattern seen among girls could develop as vaccination among boys becomes more widely accepted and coverage increases.

      According to the researchers, the current patterns of HPV vaccination may not be adequate to reverse the current geographic disparities in HPV-related cancer incidence and mortality. They suggest that strengthening adolescent preventive healthcare use may be particularly important to increase completion of the HPV vaccine course.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of a man in a suit smiling in front of an Oncology Nursing News background
      Gynecologic Cancers
      Related Content

      Graphic of endometrial cancer cells

      Selinexor Maintenance Offers Durable Benefit in Advanced Endometrial Cancer

      Jax DiEugenio
      June 27th 2025
      Article

      In TP53 wild-type advanced or recurrent endometrial cancer, selinexor improved multiple time-to-event outcomes vs placebo.


      The Vitals

      Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

      Lindsay Fischer
      June 15th 2023
      Podcast

      Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.


      Image of icons representing different organs in a circle with the female reproductive system in the middle under a magnifying glass

      Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

      Chris Ryan
      June 23rd 2025
      Article

      The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.


      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      January 2nd 2023
      Podcast

      In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.


      AI-generated graphic of cancer cells

      T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

      Chris Ryan
      June 2nd 2025
      Article

      Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.


      Graphic depicting the female reproductive system with cancer cells surrounding

      Adavosertib Yields Preliminary Safety Concerns, Antitumor Activity in USC

      Ashley Chan
      May 12th 2025
      Article

      Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking adavosertib.

      Related Content

      Graphic of endometrial cancer cells

      Selinexor Maintenance Offers Durable Benefit in Advanced Endometrial Cancer

      Jax DiEugenio
      June 27th 2025
      Article

      In TP53 wild-type advanced or recurrent endometrial cancer, selinexor improved multiple time-to-event outcomes vs placebo.


      The Vitals

      Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

      Lindsay Fischer
      June 15th 2023
      Podcast

      Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.


      Image of icons representing different organs in a circle with the female reproductive system in the middle under a magnifying glass

      Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

      Chris Ryan
      June 23rd 2025
      Article

      The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.


      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      January 2nd 2023
      Podcast

      In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.


      AI-generated graphic of cancer cells

      T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors

      Chris Ryan
      June 2nd 2025
      Article

      Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.


      Graphic depicting the female reproductive system with cancer cells surrounding

      Adavosertib Yields Preliminary Safety Concerns, Antitumor Activity in USC

      Ashley Chan
      May 12th 2025
      Article

      Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking adavosertib.

      Latest Conference Coverage

      Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

      Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

      Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer

      Understanding How On-Target and Off-Target ADC Toxicities Work

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.